New data indicates curcumin's lack of clinical efficacy in treatment of plaque psoriasis

New data published in the journal of the American Academy of dermatology has called into question anecdotal evidence linking curcumin to an improvement in psoriasis symptoms. The research suggests that any benefits derived from use of the compound, which is found in the spice turmeric, are as a result of the placebo effect rather than any therapeutic activity.

The study, which was carried out by researchers based at the University of Pennsylvania School of Medicine in the USA, was a Phase II open-label examination of a daily 4.5g dose of an oral curcuminoid C3 complex in 12 patients suffering from plaque psoriasis. Primary efficacy endpoints included Psoriasis Area and Severity Score and a physician assessment of symptoms.

The results showed that, in the intention-to-treat group, the response rate was 16.7%, with all subjects who showed such improvement achieving PASI-75. No study related adverse events were observed.